LYVE1 and neoplasm: Quantitative analyses of CD31-positive and LYVE-1-positive vessels showed significant reductions in the tumor microvascular and lymphatic vessel densities in anakinra-treated tumors versus untreated tumors (*p<0.05, **p<0.01; Figure 6C).